

## Comparison of ivermectin, oxibendazole and pyrantel pamoate in suppressing fecal egg output in horses

Claude A. Piché, Murray J. Kennedy, Herbert A. Herbers, Kathleen M. Newcomb

### Abstract

Thirty resident horses at a boarding stable in Alberta were used to evaluate the relative efficacies of ivermectin, oxibendazole, and pyrantel pamoate in reducing fecal egg output in adult horses under routine management conditions during spring and early summer, and to more clearly define the duration of suppression of fecal egg production following anthelmintic treatment. Horses were blocked according to pretreatment egg counts and randomly assigned to one of three treatments: pyrantel pamoate at 6.6 mg/kg body weight; oxibendazole at 10 mg/kg body weight; or ivermectin at 200 µg/kg body weight. All treatments were administered orally as a paste on day 0. Fecal samples were collected for examination by the modified Wisconsin procedure before treatment, and then at 4–11 day intervals up to day 72.

Very few if any strongyle eggs were found in the feces of any horses up to day 35. On days 42, 50 and 57, the geometric mean egg count for the ivermectin group was significantly ( $p < 0.05$ ) lower than that for the oxibendazole or pyrantel pamoate groups. Based on a survival curve analysis of the data, the mean number of days for recurrence of eggs in the feces was significantly longer for the ivermectin group than for the oxibendazole and pyrantel pamoate groups.

Under conditions encountered in this study, the posttreatment interval to resumption of fecal egg output in horses treated with ivermectin was eight to nine weeks, compared with five to six weeks for horses treated with oxibendazole or pyrantel pamoate.

### Résumé

**Comparaison de l'efficacité de l'ivermectin, de l'oxibendazole et du pamoate de pyrantel pour éliminer les oeufs dans les matières fécales chez les équins**

MSD Agvet, P.O. Box 1005, Pointe Claire-Dorval, Québec H9R 4P8 (Piché); Animal Health Division, Alberta Agriculture, 6909 - 116 Street, Edmonton, Alberta T6H 4P2 (Kennedy); 52024 Range Road 225, Sherwood Park, Alberta T8C 1C5 (Herbers); MSD Agvet, P.O. Box 2000, Rahway, New Jersey, USA (Newcomb).

This study was wholly supported by MSD Agvet Division of Merck Frosst Canada Inc.

Trente chevaux, en pension dans une écurie en Alberta, ont été évalués pour déterminer l'efficacité relative de l'ivermectin, de l'oxibendazole et du pamoate de pyrantel quant à la diminution du nombre d'oeufs éliminés dans les matières fécales chez les sujets adultes gardés dans des conditions normales de régie, au printemps et au début de l'été. Les auteurs voulaient, par cette étude, préciser plus clairement la durée de la suppression de la production d'oeufs dans les matières fécales suite au traitement anthelmintique. Les chevaux ont été assignés au hasard à l'un des trois traitements : pamoate de pyrantel 6,6 mg/kg; oxibendazole 10 mg/kg ou ivermectin 200 µg/kg. Tous les traitements ont été administrés *per os* sous forme de pâte au jour 0. Des échantillons de matières fécales ont été récoltés pour examen par la méthode Wisconsin modifiée avant traitement, puis à des intervalles de 4 et 11 jours, jusqu'au 72<sup>ème</sup> jour.

En règle générale, aucun oeuf de strongles n'était présent dans les matières fécales des chevaux jusqu'au 35<sup>ème</sup> jour. Aux jours 42, 50 et 57, la moyenne géométrique du nombre d'oeufs pour le groupe traité à l'ivermectin était plus basse de façon significative ( $p < 0,05$ ) comparativement aux groupes traités à l'oxibendazole ou au pamoate de pyrantel. Basée sur une courbe d'analyse à partir du suivi, la moyenne du nombre de jours pour la réapparition d'oeufs dans les matières fécales était plus longue de façon significative pour le groupe traité à l'ivermectin comparativement aux groupes traités à l'oxibendazole ou au pamoate de pyrantel.

Dans les conditions rencontrées dans cette étude, l'intervalle de temps posttraitement, pour la réapparition d'élimination d'oeufs dans les matières fécales chez les chevaux traités à l'ivermectin était de 8 à 9 semaines comparativement à 5 à 6 semaines pour les chevaux traités à l'oxibendazole ou au pamoate de pyrantel.

(Traduit par Dr Thérèse Lanthier)

## Introduction

Parasite control is an important aspect of equine health management which has relied primarily on the use of anthelmintics and, to a lesser extent, pasture hygiene (1-3). Many drugs are available for control of parasites; the activity of these drugs has been reported (4). Unfortunately, little research has been conducted which directly compares the posttreatment duration of suppression of fecal egg output after treatment with various anthelmintics. This information is essential for determining appropriate intervals between treatments. The purpose of this study was to evaluate the level and duration of suppression of fecal egg output by ivermectin, oxbendazole, and pyrantel pamoate in mature horses on pasture in western Canada.

## Materials and methods

The study was conducted at a boarding stable during the spring and early summer months, using thirty horses ranging in age from four to 15 years. Prior to the initiation of the study, most of the horses in the stable had been treated with ivermectin or pyrantel pamoate at twelve week intervals. Horses were housed individually in box stalls during the evening and were turned out to a common permanent pasture of approximately 10 acres during the day. On day -7, a fecal sample was obtained from each horse in the study and the number of strongyle-type (strongyle) eggs per 5 g of feces was determined by the modified Wisconsin method (5). Egg counts were expressed as the number of eggs per gram (epg). Eggs of other equine parasites (e.g. *Parascaris equorum*) were not observed in samples from horses included in the trial, and fecal larval cultures were not performed to differentiate eggs of small strongyles from those of large strongyles. The horses were ranked in descending order on the basis of strongyle egg count, and sequentially stratified into 10 groups of three. Three treatments were randomly allocated to the horses in each group. Group 1 contained 10 horses and each horse was given pyrantel pamoate (Strongid P, rogar/STB, London, Ontario) orally as a paste at 6.6 mg of pyrantel base per kg of body weight. Group 2 contained 10 horses and each horse was given oxbendazole (Anthelcide Eq, Norden Laboratories, Mississauga, Ontario) orally as a paste at 10 mg of oxbendazole per kg of body weight. Group 3 contained 10 horses and each horse was given ivermectin (Eqvalan Paste, MSD Agvet, Kirkland, Quebec) orally as a paste at 200 µg of ivermectin per kg of body weight. All treatments were administered on day 0. A girth tape, calibrated to correlate girth circumference to weight, was used to estimate the body weight for each horse prior to treatment. A fecal sample was obtained from each horse before treatment on day 0, and every 4-11 days thereafter until day 72 for fecal egg counting, according to the procedures established on day -7.

Individual egg counts within treatments were highly variable; therefore, data were transformed to the log<sub>e</sub> (x + 1), and the geometric mean strongyle egg count was computed for each sampling time. Examination of the residuals indicated the distribution of the transformed data was nonnormal, and Friedman's non-

parametric test for a randomized complete-block design was used to detect differences among the treatment groups (6). Differences were declared significant when  $p < 0.05$ .

An analysis was conducted to estimate the time from treatment to the first appearance of strongyle eggs in the feces. Survival curves were estimated using the product limit method and were compared using the log rank test and by the Wilcoxin rank test (6). Statistical significance was declared when  $p < 0.05$ .

Four horses were permanently removed from the stable at some point during the study and were unavailable for sampling after that time. One horse from group 1 was removed from the stable after day 50. One horse from group 2 was removed after day 22 and another after day 28. One horse from group 3 was removed after day 50. Data for these horses are included in all calculations and analyses for as long as the horses were present for sampling. Occasional samples were not available for testing during the trial.

## Results

Geometric mean strongyle egg counts, ranges of actual values, and the proportion of samples from each treatment group found to contain strongyle eggs at each sampling time are presented in Table 1. With the exception of three horses in group 2, and two horses in group 3, the same horses were positive for nematode eggs in their feces on samplings taken on days -7 and 0.

All horses treated with pyrantel pamoate (group 1) had reduced strongyle egg counts (<1 epg) from day 7 through day 35. For the majority of the group, egg counts began to increase slightly between day 35 and day 42. The geometric mean egg count approached or exceeded the pretreatment value at all sampling after day 42. Feces of all horses treated with pyrantel pamoate were negative for strongyle eggs on one sampling date (day 22).

Findings for horses treated with oxbendazole (group 2) were similar to those treated with pyrantel pamoate. From day 7 to day 35, individual egg counts in this group of horses were <1 epg, and a moderate increase was noted from day 42 to day 72. Feces of horses treated with oxbendazole were negative for strongyle eggs on days 18 and 22.

Treatment of horses with ivermectin (group 3) reduced individual strongyle egg counts of 0 or <1 epg from day 7 through day 50. The geometric mean count reached the pretreatment level by day 72. Feces of all horses treated with ivermectin were negative for strongyle eggs on days 7, 18, 22, 28 and 42.

Comparisons of the geometric mean egg count revealed significant ( $p < 0.05$ ) differences among treatments on days 42, 50 and 57. At each of these sampling times, the geometric mean fecal egg count for the ivermectin group was significantly lower than for the pyrantel pamoate or oxbendazole groups.

Survival curve analysis indicated treatment differences for the number of days until recurrence of eggs in the feces. The mean interval was calculated to be 35.5 days for the pyrantel pamoate group, 33.3 days for the oxbendazole group, and 52.5 days for the ivermectin group. Results of the log rank and

**Table 1. Geometric mean strongyle-type egg counts, range of actual values, and proportion of horses shedding eggs in the feces before and after treatment**

| Sampling day | Pyrantel pamoate              |               | Oxibendazole                  |               | Ivermectin                    |               |
|--------------|-------------------------------|---------------|-------------------------------|---------------|-------------------------------|---------------|
|              | Geometric mean epg            | #pos #sampled | Geometric mean epg            | #pos #sampled | Geometric mean epg            | #pos #sampled |
| -7           | 6.04 <sup>a</sup><br>(0-900)* | 6/10          | 6.38 <sup>a</sup><br>(0-260)  | 6/10          | 7.25 <sup>a</sup><br>(0-259)  | 6/10          |
| 0            | 9.08 <sup>a</sup><br>(0-271)  | 6/10          | 16.80 <sup>a</sup><br>(0-296) | 9/10          | 6.33 <sup>a</sup><br>(0-1066) | 6/10          |
| 7            | 0.03 <sup>a</sup><br>(0-0.4)  | 1/10          | 0.08 <sup>a</sup><br>(0-1)    | 1/9           | 0.00 <sup>a</sup><br>(0)      | 0/10          |
| 18           | 0.02 <sup>a</sup><br>(0-0.2)  | 1/10          | 0.00 <sup>a</sup><br>(0)      | 0/10          | 0.00 <sup>a</sup><br>(0)      | 0/10          |
| 22           | 0.00 <sup>a</sup><br>(0)      | 0/10          | 0.00 <sup>a</sup><br>(0)      | 0/10          | 0.00 <sup>a</sup><br>(0)      | 0/10          |
| 28           | 0.07 <sup>a</sup><br>(0-0.4)  | 2/10          | 0.02 <sup>a</sup><br>(0-0.2)  | 1/9           | 0.00 <sup>a</sup><br>(0)      | 0/10          |
| 35           | 0.18 <sup>a</sup><br>(0-2)    | 2/10          | 0.35 <sup>a</sup><br>(0-0.6)  | 5/8           | 0.09 <sup>a</sup><br>(0-0.6)  | 3/10          |
| 42           | 1.90 <sup>a</sup><br>(0-41)   | 9/10          | 1.97 <sup>a</sup><br>(0.2-44) | 8/8           | 0.00 <sup>b</sup><br>(0)      | 0/10          |
| 50           | 4.77 <sup>a</sup><br>(0-178)  | 9/10          | 3.04 <sup>a</sup><br>(0-85)   | 6/8           | 0.06 <sup>b</sup><br>(0-0.2)  | 3/10          |
| 57           | 5.63 <sup>a</sup><br>(0-206)  | 8/9           | 5.86 <sup>a</sup><br>(0-134)  | 6/7           | 0.54 <sup>b</sup><br>(0-7)    | 2/8           |
| 64           | 6.95 <sup>a</sup><br>(0-187)  | 8/9           | 6.50 <sup>a</sup><br>(0.2-70) | 7/7           | 3.56 <sup>a</sup><br>(0-589)  | 5/9           |
| 72           | 6.29 <sup>a</sup><br>(0-156)  | 8/9           | 4.20 <sup>a</sup><br>(0-76)   | 6/8           | 7.22 <sup>a</sup><br>(0-750)  | 6/9           |

<sup>a,b</sup>Means in same row with different superscripts are significantly different ( $p < 0.05$ )

\*Values in parentheses are the ranges of actual egg counts

Wilcoxin rank tests were in agreement in that the mean number of days to recurrence of eggs in the feces was found to be significantly ( $p < 0.05$ ) greater for the ivermectin group than for the oxibendazole or pyrantel pamoate groups.

## Discussion

In this study, ivermectin was found to be more effective than oxibendazole or pyrantel pamoate in suppressing strongylid fecal egg output in mature horses on pasture. From day 42 to day 57 after treatment, the mean number of eggs in feces of horses treated with pyrantel pamoate or oxibendazole was significantly greater than the mean for horses treated with ivermectin.

It is recognized that the majority of strongylid eggs passed in the feces of horses are those of small strongyles and that the prepatent period of small strongyles is six to eight weeks or longer (7-9). Few, if any, nematode ova were detected for at least eight weeks in fecal samples from horses treated with ivermectin. In contrast, nematode ova were detected in feces of the majority of horses by the sixth week after treatment with oxibendazole or pyrantel pamoate. This finding indicates that ivermectin provided better control of small strongyle larvae than did oxibendazole or pyrantel pamoate. These results are consistent with those of previously published studies in which the post-treatment fecal egg counts in ivermectin-treated horses remained negative or very low for at least eight weeks and where counts increased by six weeks posttreatment

in pyrantel or benzimidazole-treated horses (9-11). The treatment differences in mean number of days until recurrence of eggs in the feces are similar to those reported in a U.K. study where the posttreatment interval was significantly longer for ivermectin than for pyrantel or fenbendazole (12).

Although evaluation of, or recommendations for, pasture and stable management practices is beyond the scope of this trial, it has been proposed that levels of parasitism may be substantially reduced in grazing horses by integration of good pasture management, good sanitation practices, and correct use of effective anthelmintic therapy to control shedding of eggs (2,3,9). Recently conducted studies have demonstrated that the strategic use of anthelmintics, early in the grazing season, can eliminate the spring-summer rise in fecal egg counts (13,14). This can reduce the seasonal rise in pasture infectivity later in the grazing season. It is important, however, that attention be paid in the choice of the anthelmintic. Factors such as the spectrum of activity and the posttreatment interval to resumption of fecal egg output must be considered to ensure adequate parasite control.

## Acknowledgments

We gratefully acknowledge the statistical analyses provided by Dr. Richard Trout, Associate Professor of Statistics at Rutgers University, New Brunswick, New Jersey, USA.

CVJ

## References

1. Drudge JH, Lyons ET. Control of intestinal parasites in the horse. *J Am Vet Med Assoc* 1966; 148: 378-383.
2. Uhlinger C, Johnstone C. Prevalence of benzimidazole-resistant small strongyles in horses in a southeastern Pennsylvania practice. *J Am Vet Med Assoc* 1985; 187: 1362-1366.
3. Scoggins RD, Di Pietro J. Maintaining effective internal parasite control. *Animal Health and Nutrition*, 1986: 6-10.
4. Di Pietro JA, Todd KS. Anthelmintics used in treatment of parasitic infections of horses. *Equine Pract* 1989; 11: 5-15.
5. Cox DD, Todd AC. Survey of gastrointestinal parasitism in Wisconsin dairy cattle. *J Am Vet Med Assoc* 1962; 141: 706-709.
6. Steel RGB, Torrie JH. Principles and Procedures of Statistics. New York: McGraw-Hill, 1960: 400-411.
7. Round MC. The prepatent period of some horse nematodes determined by experimental infection. *J Helminthol* 1969; 23: 185-192.
8. Reinemeyer CR. Small strongyles: Recent advances. *Vet Clin N Am (Equine Pract)* 1986; 2: 281-312.
9. Herd RP, Miller TB, Gabel AA. A field evaluation of probenzimidazole, benzimidazole and non-benzimidazole anthelmintics in horses. *J Am Vet Med Assoc* 1981; 179: 686-691.
10. Slocombe JOD, Cote JF. Effectiveness of ivermectin paste for removal of nematodes in the horse. *Can Vet J* 1984; 386-388.
11. Baker NF, Miller JE, Madigan JE, Fulton R, Seward RL. Anthelmintic action of ivermectin, oxbendazole and pyrantel pamoate against thiabendazole-resistant small strongyles of horses. *Equine Pract* 1984; 6: 8-19.
12. Lumsden CG, Quan-Taylor R, Smith SM, Weshbrooke IM. Field efficacy of ivermectin, fenbendazole and pyrantel embonate paste anthelmintics in horses. *Vet Rec* 1989; 125: 497-499.
13. Slocombe O. Strategic control of strongyles with ivermectin in mature horses in Ontario. *Proc Am Assoc Vet Parasitol* 1989; 26
14. Slocombe JOD, Dobson H, Lumsden JH, Lake MC. Strategic control of strongyles with ivermectin in yearling ponies. *Proc VII Int Cong Parasitol* 1990: 863.

## Canadian Journal of Veterinary Research/ Revue Canadienne de Recherche Vétérinaire

### Abstract

### Prediction of the halothane (Hal) genotypes by means of linked marker loci (Phi, Po2, Pgd) in Quebec Landrace pigs

F. Doizé, I. Roux, B. Martineau-Doizé, L. DeRoth

Flow cytometry was investigated for detection of bovine viral diarrhoea virus (BVDV) in peripheral blood mononuclear leukocytes of persistently infected cattle. The mononuclear leukocytes were purified by sedimentation in a gradient of Ficoll-Paque, fixed, permeabilized, and then labelled by indirect immunofluorescence using biotinylated immunoglobulins from a porcine antiserum to

BVDV. Flow cytometric analysis of blood samples obtained from persistently infected cattle revealed virus in 3.0-21.0% (mean  $\pm$  SD, 11.2%  $\pm$  6.4%) of the mononuclear leukocytes. Fluorescent cells were not observed in controls. Flow cytometric detection of BVDV in blood cells of persistently infected bovines is a rapid and objective technique which does not require cell culture facilities.

(*Can J Vet Res* 1990; 54: 397-399)

### Abstract

### Flow cytometric detection of bovine viral diarrhoea virus in peripheral blood leukocytes of persistently infected cattle

Per Qvist, Bent Aasted, Buchardt Block, Anders Meyling, Leif Ronsholt, Hans Houe

Quebec Landrace pigs (n=896) were halothane tested and blood samples were taken for the determination of Phi, Po2 and Pgd phenotypes. The prevalence of the halothane positive pigs was 5.3%. The frequencies of the favorable alleles Phi<sup>A</sup>, Po2<sup>S</sup> and Pgd<sup>A</sup> were respectively 29.2%, 39.6% and 64.4%. The highest linkage disequilibrium was

found between Hal-Phi (0.0606) followed by Hal-Pgd (0.0428) and Hal-Po2 (-0.0308). Alleles Phi<sup>B</sup>, Pgd<sup>B</sup> and Po2<sup>F</sup> were associated respectively with 97%, 81% and 74% of Hal<sup>n</sup> haplotypes. It was concluded that selection to increase the favorable marker loci Phi<sup>A</sup> and Pgd<sup>A</sup> would reduce the Hal<sup>n</sup> frequency in Quebec Landrace pigs.

(*Can J Vet Res* 1990; 54: 469-472)